Day One Biopharmaceuticals, Inc. (DAWN)
$12.895
+0.10 (+0.82%)
Rating:
Recommendation:
-
| Symbol | DAWN |
|---|---|
| Price | $12.895 |
| Beta | 0.000 |
| Volume Avg. | 0.66M |
| Market Cap | 948.906M |
| Shares () | - |
| 52 Week Range | 5.44-28.35 |
| 1y Target Est | - |
| DCF Unlevered | DAWN DCF -> | |
|---|---|---|
| DCF Levered | DAWN LDCF -> | |
| ROE | -42.27% | Strong Sell |
| ROA | -40.73% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 5.13% | Neutral |
| P/E | -7.01 | Strong Sell |
| P/B | 2.54 | Strong Buy |
Latest DAWN news
About
Download (Excel)Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.